[go: up one dir, main page]

DK3453711T3 - Llp2a-bisphosphonatkonjugater til behandling mod osteoporose - Google Patents

Llp2a-bisphosphonatkonjugater til behandling mod osteoporose Download PDF

Info

Publication number
DK3453711T3
DK3453711T3 DK18187424.9T DK18187424T DK3453711T3 DK 3453711 T3 DK3453711 T3 DK 3453711T3 DK 18187424 T DK18187424 T DK 18187424T DK 3453711 T3 DK3453711 T3 DK 3453711T3
Authority
DK
Denmark
Prior art keywords
llp2a
osteoporosis
treatment
bisphosphonate conjugates
bisphosphonate
Prior art date
Application number
DK18187424.9T
Other languages
English (en)
Inventor
Kit S Lam
Ruiwu Liu
Wei Yao
Nancy Lane
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/050381 external-priority patent/WO2012031228A2/en
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK3453711T3 publication Critical patent/DK3453711T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • C07K5/0817Tripeptides with the first amino acid being basic the first amino acid being Arg
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1019Tetrapeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK18187424.9T 2011-09-02 2012-01-19 Llp2a-bisphosphonatkonjugater til behandling mod osteoporose DK3453711T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2011/050381 WO2012031228A2 (en) 2010-09-02 2011-09-02 Llp2a-bisphosphonate conjugates for osteoporosis treatment
EP12826522.0A EP2753626B1 (en) 2011-09-02 2012-01-19 Llp2a-bisphosphonate conjugates for osteoporosis treatment

Publications (1)

Publication Number Publication Date
DK3453711T3 true DK3453711T3 (da) 2021-10-18

Family

ID=47757243

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18187424.9T DK3453711T3 (da) 2011-09-02 2012-01-19 Llp2a-bisphosphonatkonjugater til behandling mod osteoporose

Country Status (3)

Country Link
EP (2) EP3453711B1 (da)
DK (1) DK3453711T3 (da)
WO (1) WO2013032527A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015051327A1 (en) * 2013-10-04 2015-04-09 The Regents Of The University Of California Treating inflammation using llp2a-bisphosphonate conjugates and mesenchymal stem cells
EP3402803A4 (en) * 2016-01-14 2019-09-04 The Regents of The University of California METHOD OF TREATING ESTONEONE CRACKING WITH LLP2A-BISPHOSPHONATE COMPOUNDS
ES2953519T3 (es) 2016-12-15 2023-11-14 Nestle Sa Composiciones y métodos que modulan la vitamina D y el contenido mineral óseo en un animal de compañía
WO2020018941A1 (en) 2018-07-19 2020-01-23 The Regents Of The University Of California Peptides for activation of cell signaling in osteoprogenitor cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US20020128301A1 (en) * 1998-02-13 2002-09-12 Medivir AB Non-nucleoside reverse transcriptase inhibitors
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
PT1133558E (pt) 1998-11-27 2007-01-31 Ucb Sa Composições e métodos para aumentar a mineralização óssea
JP2003532632A (ja) * 1999-12-17 2003-11-05 アライアッド・ファーマシューティカルズ・インコーポレーテッド 新規の複素環
JP2005511593A (ja) 2001-11-08 2005-04-28 メルク エンド カムパニー インコーポレーテッド 骨粗鬆症を治療するための組成物及び方法
JP2006503615A (ja) 2002-09-30 2006-02-02 リージェン バイオテック インコーポレーテッド 硫酸カルシウム及び粘性を有するポリマーを含む骨形成および骨硬化を促進させる骨充填用組成物
US6976816B2 (en) 2003-08-01 2005-12-20 Dana Corporation Combination lock washer and spindle bearing assembly
US7531518B2 (en) 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7576175B2 (en) 2004-05-27 2009-08-18 The Regents Of The University Of California Alpha-4 beta-1 integrin ligands for imaging and therapy
DE602006021318D1 (de) 2005-08-31 2011-05-26 Monsanto Technology Llc Insektizidzusammensetzungen und verfahren zur hersn
WO2008036449A2 (en) 2006-06-29 2008-03-27 The Regents Of The University Of California Chemical antibodies for immunotherapy and imaging
EP2046391A4 (en) * 2006-08-02 2013-03-20 Univ Nebraska ACTIVE SUBSTRATE, SYNTHESIS AND METHOD FOR THEIR USE
US8486370B2 (en) * 2006-09-08 2013-07-16 The Regents Of The University Of California Heterocyclic ligands for integrin imaging and therapy

Also Published As

Publication number Publication date
WO2013032527A1 (en) 2013-03-07
EP2753626A4 (en) 2015-03-25
EP2753626A1 (en) 2014-07-16
EP2753626B1 (en) 2018-08-08
EP3453711A1 (en) 2019-03-13
EP3453711B1 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
ES1115080Y (es) Calzado de suela dividida
DK2768479T3 (da) Hjælpestoffer til nikotin-indeholdende terapeutiske sammensætninger
EP2713939A4 (en) DENTAL IMPLANT
CO6781554A2 (es) Agentes moduladores de s1p
DK2793915T3 (da) Implanterbare materialer til knoglereparation
EP2663304A4 (en) COMBINATION THERAPY
EP2755612A4 (en) MARKET FRAME FOR ANKLE
BR112013033332A2 (pt) calçado
BR112014012778A2 (pt) embalagem de cateter
BR112014012016A2 (pt) compostos
BR112013033974A2 (pt) terapia de combinação
DK2760886T3 (da) Immunocytokin-kombinationsterapi
DK3395357T3 (da) Sammensætning til kontrolleret ovariestimulering
HRP20160887T1 (hr) Formulacije testosterona
FI20115876A0 (fi) Yhdistelmähoito
DE112012003860A5 (de) Füllschuh
DK2734212T3 (da) Sammensætninger omfattende diclofenac til behandling af postoperativ smerte
BR112014012043A2 (pt) emplastro
DK3473267T3 (da) Individualiserede vacciner mod cancer
BR112013020339A2 (pt) composição de tratamento de sementes
DK2455064T3 (da) Indretning til behandling af periodontal sygdom
FI20115640A0 (fi) Yhdistelmähoito
FR2972625B1 (fr) Implant dentaire
DK3453711T3 (da) Llp2a-bisphosphonatkonjugater til behandling mod osteoporose